Sanctuary Advisors LLC Reduces Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Sanctuary Advisors LLC trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,183 shares of the medical research company’s stock after selling 196 shares during the quarter. Sanctuary Advisors LLC’s holdings in Charles River Laboratories International were worth $3,172,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares during the last quarter. Mizuho Securities USA LLC increased its holdings in Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after acquiring an additional 92,895 shares in the last quarter. Premier Fund Managers Ltd increased its holdings in Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock valued at $49,573,000 after acquiring an additional 90,000 shares in the last quarter. JPMorgan Chase & Co. raised its position in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after purchasing an additional 47,221 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

CRL has been the subject of several research reports. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. UBS Group reissued a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Robert W. Baird dropped their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $195.71.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE:CRL opened at $163.11 on Friday. The stock has a 50-day simple moving average of $172.84 and a 200-day simple moving average of $188.09. The stock has a market capitalization of $8.34 billion, a P/E ratio of 1,087.39, a PEG ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the firm earned $2.46 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).